Physician profile
Jonathan E Reitman
NPI 1922157320
$11,447.04
in general payments reported to CMS, 2019-2025
41 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 91% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,094 · 2020: $1,168 · 2021: $1,817 · 2022: $1,176 · 2023: $1,692 · 2024: $1,976 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,192.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,243.28 | 2019-2025 | |
| Gilead Sciences, INC. | $1,803.40 | 2019-2025 | |
| Viiv Healthcare Company | $1,353.32 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $885.46 | 2020-2025 | Caplyta |
| Indivior INC. | $501.36 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.53 | 2019-2025 | Xifaxan, Relistor |
| Emd Serono, INC. | $441.52 | 2019-2025 | Serostim |
| Theratechnologies INC. | $318.54 | 2019-2023 | Trogarzo, Egrifta |
| Takeda Pharmaceuticals U.S.A., INC. | $306.28 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $263.66 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $250.10 | 2019-2022 | |
| Lundbeck LLC | $246.18 | 2019-2025 | Rexulti, Abilify Maintena |
| Napo Pharmaceuticals INC | $242.49 | 2019-2024 | Mytesi |
| Janssen Biotech, INC. | $227.37 | 2019-2023 | Symtuza |
| Orexo US, INC. | $202.51 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $195.06 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $194.92 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $136.83 | 2019-2025 | Pifeltro |
| Teva Pharmaceuticals USA, INC. | $136.19 | 2019-2023 | Uzedy, Austedo Xr |
| Lilly USA, LLC | $116.90 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $113.65 | 2023-2025 | Repatha, Otezla, Otezla |
| Neuronetics, INC. | $112.10 | 2023 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $96.82 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $83.51 | 2019-2024 | Fanapt |
| Allergan, INC. | $82.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $59.47 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $54.64 | 2019-2023 | Breztri |
| Antares Pharma, INC. | $28.48 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.83 | 2020 | |
| Alkermes, INC. | $24.66 | 2020 | |
| Tolmar, INC. | $24.12 | 2025 | Jatenzo |
| Mdd US Operations, LLC | $19.80 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.56 | 2021 | |
| Tris Pharma INC | $19.21 | 2023 | Dyanavel Xr |
| Astellas Pharma US INC | $18.84 | 2021 | |
| Optos, INC. | $17.57 | 2021 | |
| Uswm, LLC | $17.41 | 2022 | |
| Alfasigma USA, INC. | $17.36 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.94 | 2019 | |
| Eisai INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Reitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.